0001104659-11-056940.txt : 20120103 0001104659-11-056940.hdr.sgml : 20120102 20111020150138 ACCESSION NUMBER: 0001104659-11-056940 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20111020 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ONCOSEC MEDICAL Inc CENTRAL INDEX KEY: 0001444307 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 980573252 STATE OF INCORPORATION: NV FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 4690 EXECUTIVE DRIVE SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (855) 662-6732 MAIL ADDRESS: STREET 1: 4690 EXECUTIVE DRIVE SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: NetVentory Solutions, Inc. DATE OF NAME CHANGE: 20080902 CORRESP 1 filename1.htm

 

 

VIA EDGAR

 

October 20, 2011

 

United States Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

 

Attention: Mara L. Ransom, Assistant Director
cc: Catherine T. Brown, Staff Attorney
cc: Angie Kim, Staff Attorney

 

Re:

OncoSec Medical Incorporated

 

Registration Statement on Form S-1

 

File No. 333-175779

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the Securities Act of 1933, as amended, OncoSec Medical Incorporated, a Nevada corporation (the “Company”), hereby requests that the Securities and Exchange Commission (“SEC”) take appropriate action to cause the above-referenced Registration Statement to become effective at 1:00 PM Eastern Standard Time on October 21, 2011 or as soon thereafter as possible.

 

The Company hereby acknowledges that:

 

·                  Should the SEC or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the SEC from taking any action with respect to the filing;

 

·                  The action of the SEC or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

·                  The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the SEC or any person under the federal securities laws of the United States.

 

Should you have any questions or require any additional information with respect to this filing, please contact Jeannette Filippone or Steven G. Rowles at (858) 314-5412 or by facsimile at (858) 523-2829.  Thank you for your assistance and cooperation.

 

Yours very truly,

 

 

 

/s/ Punit Dhillon

 

ONCOSEC MEDICAL INCORPORATED

 

 

Punit Dhillon

President and CEO

Direct Line:    (855) OncoSec (662-6732) Ext: 501

 

OncoSec Medical Incorporated · 4690 Executive Drive Suite 250 · San Diego, California 92121

Telephone: (855) OncoSec (662-6732) or (858) 224-0090 · Fax: (858) 430-3832

 


GRAPHIC 2 g211315bci001.jpg GRAPHIC begin 644 g211315bci001.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T3QEXPL_" M&EBXF7SKF7*V]N#@N?4^@'FU_P`67DKMF*VD:W@'8(K'^=>V^!O#=OX:\-6T"1J+F9!)'?B?X@T"\%OJLDM_;*VV6*X_UL?K MACSGV->]UY9\9?#==R,/Y'WI$U;39+C[.FH6K3%MOEB92V?3&CH'U+4+>T#=/- MD"D_0=Z9IOB'1M9)73=3MKIAR5CD!8?AUKQ>R^'?B[QANUF^FCA:X^=9+QSO M<'IA0#@>G2N;U/3-6\'Z_P#9YF-M>VY#QRQ-P1V93Z4`?3M17%S!:0F:YFCA MB7J\C!5'XFL+2O%4$_@2'Q+>X11;&28+_>7@@?5AQ]:\.UC6]<\>:\J,))GF M?;;6<9^6,>@'3IU)H$>[+XW\+--Y0U^QWYQ_KAC\^E;4,T5Q$LL,J2QMRKHP M(/T(KQ*+X*^(9+8/)>V$4A&?*)8X]L@8KL=)-[X%\$V.F7IA@NI)Y$$F\%!D MEA@],D=`:BES>)_#<@GU\6%OI49VRO';;R;AW!&"/J#TK:$V])*S[7.><$G[KNNYY?\2/B1>V6I M2Z'H+M2^TH69+Z0NK=_G)_45]"Z%XHT37K.*73KV$Y49A+!73V*]:U(/%6TWXC M^'`9575XD3DF*4RH/J`2*]M\+WESJ'AC3;R\8M<36Z/(Q7;EB.>.U:M5[V\@ MTZQGO;AMD-O&TCGT`&30(=1PJC\365!XT\,7$_DQ:[8M M(3@#S@,_G7ANJZMK?Q$\3)"@:0S.5MK7=A(E]3^')-:VM_"+6M'T>34%NK:\ M\E=\L,:D,%'4C/7'X4#/=@0P#*00>01WI:\:^$7BZYBU,>';R9I+:=2;;><^ M6X&=H]B,\>H]ZZWXF^-)?#&FQV>GL!J%X#M?KY2#JWU[#\?2@1U&HZ[I&D?\ MA'4K:U)Z++*%)_#K45AXHT'5)!%8ZQ9SR'HBS#ST444" M"BBB@`HHHH`***JS:G8V]_!8374275P"8H2WS.!U(%`%JBBB@`HHHH`**R[W MQ-HFG7;VEYJ=O#<(`6C=_F`/3(HH`^:KH&+6)Q+U2Y;?GV*ZZ26.&,R2R+&BC)9F``_ M&O%OBKXWM=<>+1M+F$UK;OYDTR_=D?H`/4#)Y]?I0(C^"RL?%]TP^ZMDV[_O MM:Y/4@#XTN@1D'4F_P#1E>I_!KP_+8Z1<:S<(4>^(6$$<^6O?\2?TKRW4?\` MD=+G_L)-_P"C*!GTU7B7QJ`_X2NS./\`ER'_`*&U>W5XC\:_^1KL_P#KR'_H M;4`B34KEX?@1ID2$@3W6QOHYX.<9&>1GO7/B75C2DZ2O(THJ#J+GV.CVTH)_(X->XV&OZ1JA9;+4;>9T8JR+(-RD'!!'6M!F55+,0`.I)KUSB M/G#3O%GBKPI>^2+NZC,1^>TN\LOT*MR/PKT?Q5XJ3Q#\(9]3ME,37#)#-'G. MQMXW#Z?T->UC83RQD$>%]1.H6"P&8QF,&9-P`.,XY'/%=))\8 MO$LL3QN-/*NI4CR3R#_P*J'P\US3M$\2A]5BB>RN8S$[R(&$9R"&^G&#]:]Y MM[/0[J$36]M831L,AXXT8'\10!\Z^#Y_*\9:.Z,-WVR,<'U;']:W/BU'8M0AM4_LY;QS^[C0)YF0,\`<]J\A^,>ERVGBU M+_:?)O85PW;H?#VRBL?`VEI$H'FPB5R/XF;DG]?TKI*\[^%GC M&PN_#\&BW5S'#>V8*(LC8\U,\$9ZD=,>U=W=:E8V,?F7=Y!`O0&20+G\Z!%F MO,_BW/=W=UI>CV,\D4ACGNG\MRI*HF1T^C5Z97GT,2ZY\8-1W_-#ING"#VRX MY_\`0FH`Z?P=?G4_!^E7;-N9[9`Q)SE@,']0:\X^*?B.ZU*\FTW3+B2.UTLJ M+B2)BN^=SA4R/09_7TJWX?\`$[^&?AMV2:KWOA MS^RY/"?AJ5O-N[Z^^W:@_4NPQGGT`W"@9Z+'?:?X6\.62ZK?QVR0P)&7G?EF M"C/7DFI='\2:+X@#G2=2@NS']\1MROX'FO,%\06.I^.M2U35])U#5DM)#;Z? M;P6WFQQA202>V3U_'Z5?0ZC;:OJ7CE]#_L.TL]/>.*W46ZKT54!*@>V6%`'7>'K/2EU#5M;L=6>^%W+B4M*&CA*]57TQFE_X3[P MG]L^R?V]9^=NVXW\9^O3]:\[M+>XE\)^%O"<,KPG797N;QTX)BSG'XC^5>GP M>&-`L[!+6/2;,01`8#0J3QWR1DGWH`DU?Q#H^@1))JNH06BO]WS&Y;Z#J:;9 M>)=$U)K=++5+:=KH,851P2X7KQUXKD/`]A!XJU+4O%VJPIQ![$5Y'K7P7U>VF9M'NH;V'.525O+D7\>A^O%%%`&2/A MCXWG(ADLCL'_`#TNU*C]:ZOPQ\&E@G2Z\17,)9_$\,PS,<[2^>F.N***`/:*\U^ M(_@+6O%.NV]YIOV;RH[<1MYLA4YW$^A]:**`.K\%Z)[DN_#DL0C<[C:3-MV'_9;T]C^=%%`'*K\+O&1?RAI85? M4W";?YUZ]\/?#E[X7\,+I]^T1G,SR$1'(4''&?PHHH`U]=L)-3T>:VA($N5> M/=T+*P8`^Q(Q7+[R&V/:W23=X?(8MGTX&#](Y7)M/;0Z:%:5. MZ1L:?X;BN-#N+758`3>S>>\8;!B(P%PPZ,`H.1WJ]IFA6^F.9!/<7,N-HDN' M#%1Z#``_'K117?&C3BHI+X=%Y&#G)WUW/)M=^#^OC49[K3I[6[265G4%S$ZY M.<<\=_6LK_A6OCF0^4UDY7_:O%V_^A445J3OV=E;:?9165I"L5O"@1(U'``HHH`\P\7?!][J\EOO#LT4?FDL]I* M=J@_[+=A[&N0_P"%8^-(W,:Z80/5+E`I_P#'J**`.K\!?#37=%\26VKZD;:% M(`V8UDWNV5([<=_6O1/$GANP\4:2^GWZG&=TB;L1_GFBB@#QW5/A!XFL MIF%DL&H0@_*Z2!&_%6[_`$-,TOX5>+9[Z![FUBMD216+S3AL`'/`7-%%`[GO M=.;_`$&/P[_8R:4T<'D2ZC),&&T#'R*.Y'?H M*SK/0/$Z?#"\\-+HA@NO-"!O/0^OYUIZ/K/B/6+SR;_`,,G2[,QL))9KA78G'`51_.B MB@#G/#L'C/PM93>'+308K@"9VM]0><+$JL>K#J<=<57T;PUXITR#Q1ICV0GE MU*-WCU)IE`E;!`&.HSN/7I110!U_@.UOK#PC9V6H6'V*:V!C\O>&W`'[W'3) (SQ1110!__]D_ ` end